TDO2 and IDO1 inhibitors

US11603373B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Zhonghua Pei · South San Francisco, US
• Richard Pastor · South San Francisco, US
• Lewis Gazzard · Belmont, US
• Brendan Parr · South San Francisco, US
• Wendy Liu · Foster City, US
• Rohan Mendonca · South San Francisco, US
• Guosheng Wu · Beijing, CN
• Po-Wai Yuen · Ann Arbor, US

Key dates

• Filing date: Jun 20, 2018
• Grant date: Mar 14, 2023
• Expiry date: Jun 20, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.